Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanzacaftor/tezacaftor/deutivacaftor granule formulation in healthy adults
NCT06299709Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vanzacaftor in cystic fibrosis (CF) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at 384 hours and Area Under the Concentration Versus Time Curve at 384 hours. Started Mar 2024; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06299709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299709.